|
PRCP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64501745558709E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.7541081354675E-12 |
| Normal-vs-Stage2 |
5.736800E-03 |
| Normal-vs-Stage3 |
1.82243109492219E-12 |
| Normal-vs-Stage4 |
1.62503344114384E-12 |
| Stage1-vs-Stage2 |
2.806300E-02 |
| Stage1-vs-Stage3 |
4.537800E-02 |
| Stage1-vs-Stage4 |
2.206600E-04 |
| Stage2-vs-Stage3 |
1.898140E-03 |
| Stage2-vs-Stage4 |
1.56977999999919E-05 |
| Stage3-vs-Stage4 |
5.979900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62547753035369E-12 |
| Normal-vs-AfricanAmerican |
2.17049999973185E-07 |
| Normal-vs-Asian |
4.32439999997758E-06 |
| Caucasian-vs-AfricanAmerican |
9.812600E-01 |
| Caucasian-vs-Asian |
1.564770E-01 |
| AfricanAmerican-vs-Asian |
3.566400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.88784576649459E-12 |
| Normal-vs-Female |
1.70319314207745E-12 |
| Male-vs-Female |
4.948400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.87692133741302E-12 |
| Normal-vs-Age(41-60Yrs) |
2.61457522299224E-13 |
| Normal-vs-Age(61-80Yrs) |
4.24129953380259E-10 |
| Normal-vs-Age(81-100Yrs) |
1.434740E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.842400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.187000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.371800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.562200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.747200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.105000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.602200E-03 |
| Classical-VS-Follicular |
1.088190E-02 |
| Classical-VS-Other |
1.096840E-01 |
| Classical-VS-Normal |
7.33857419277228E-14 |
| Tall-VS-Follicular |
1.69164999999083E-05 |
| Tall-VS-Other |
8.409000E-01 |
| Tall-VS-Normal |
1.64956936998806E-12 |
| Follicular-VS-Other |
3.933700E-02 |
| Follicular-VS-Normal |
2.218800E-04 |
| Other-VS-Normal |
4.67639999945924E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.78600031933252E-10 |
| Normal-vs-N1 |
1.63080660087189E-12 |
| N0-vs-N1 |
2.996800E-04 |
|
|
